A pharmacovigilance analysis found disproportionately higher reporting rates of vascular ectasia and regional bleeding associated with sotatercept compared with other pulmonary arterial hypertension drugs. The study looked at spontaneous-report signals across treated populations and flagged safety patterns that may warrant closer review. While pharmacovigilance studies cannot establish causality and are sensitive to reporting biases, the observed disproportionality is notable for a drug used in PAH populations where vascular complications already carry clinical weight. For safety surveillance and formulary discussions, the signal increases the urgency for confirmatory analyses using registry or claims datasets to quantify absolute risks.
Get the Daily Brief